Skye Bioscience, Inc. has initiated the first patient treatment in Part C of its CBeyond Phase 2a trial, focusing on the safety and pharmacokinetics of nimacimab, a novel monoclonal antibody targeting obesity and metabolic disorders. This expansion study will evaluate higher intravenous doses (400 mg and 600 mg) over 16 weeks, aiming to enhance peripheral tissue exposure compared to the previously tested 200 mg subcutaneous dose. The study design includes a randomized, placebo-controlled approach to gather preliminary safety and pharmacokinetic data, with results expected in late 2026.

The significance of this trial lies in its potential to redefine dosing strategies for nimacimab, particularly in combination with incretin therapies like semaglutide. Previous findings indicated a 22.3% mean weight loss at 52 weeks in patients receiving the combination therapy, highlighting the need for optimized dosing to maximize efficacy. By focusing on higher peripheral exposure, Skye aims to validate the hypothesis that increased dosing can enhance therapeutic outcomes while maintaining a favorable safety profile, which is crucial for advancing to Phase 2b trials.

A key takeaway for professionals in the longevity and healthspan research fields is the emphasis on pharmacokinetics in therapeutic development. As nimacimab seeks to establish itself as a first-in-class obesity treatment, its approach to peripheral restriction and safety may offer insights into developing future therapies that minimize adverse effects while maximizing efficacy in metabolic health. This trial could set a precedent for how dosing strategies are approached in the context of combination therapies for obesity and related metabolic disorders.

Source: globenewswire.com